The 2025 ASCO® Annual Meeting

Experience live demos of our newest technologies for providers, biopharma, and research partners

Stop by our booth to discover how we are leveraging AI-enabled technologies to advance precision oncology.

Tempus Hub: Streamline ordering and get quick access to patient information through our secure online platform. Place orders tailored to your patient’s diagnosis with one-click, view comprehensive smart reports, and review patient medical history—all in one place.

Tempus One: Get real-time answers and uncover patient insights with our generative AI assistant built for healthcare providers and researchers. Just ask a question to access data-driven responses instantly.

Tempus Lens: Quickly define detailed patient cohorts using natural language processing and transform complex criteria into actionable datasets. Explore unstructured clinical data and extract nuanced insights. With Lens, the power of Tempus data is at your fingertips.

Tempus Next: Identify patients who may have deviated from care pathways and help providers close gaps in care, accelerating adoption of precision medicine.

Tempus Link: Identify prospective clinical trial patients and streamline trial workflows to accelerate clinical trial enrollment with one of the largest, data-integrated oncology trial networks in the nation.

Don't miss the opportunity to see how Tempus is offering one platform for precision oncology by harnessing AI to drive innovation, improve inefficiencies and streamline workflows.

Powering Today’s Insights for a Smarter Tomorrow: Intelligent Diagnostics and AI Solutions Across the Cancer Continuum

At Tempus, AI is infused into everything we do to optimize insights, efficiencies, and tailor patient care. Discover how we’re redefining precision oncology at scale—where our tests fuel smarter decisions and data advances care. Learn how AI, real world data and diagnostics drive innovation.

Add this to your calendar

*Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. Not CME-accredited.

A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors

A Technology-Enabled Clinical Trial Matching Program’s Impact on Patient Screening and Trial Enrollment in 2024

Clinicogenomic landscape and outcomes of metastatic colorectal cancer patients with pathogenic GNAS variants

Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment

Detection of KMT2A Partial Tandem Duplication (PTD) in AML by Whole Genome Sequencing (WGS): Addressing Limitations of Traditional Techniques in the Era of Revumenib Approval

Evaluation of large language model (LLM)-based clinical abstraction of Electronic Health Records (EHRs) for Non-Small Cell Lung Cancer (NSCLC) patients

GEMINI-NSCLC Study - Integrated Longitudinal Multi-Omic Biomarker Profiling Study of Non-Small Cell Lung Cancer (NSCLC) Patients

ImmunoDriver-1: Driver alterations (dAlts) and their Immunological Implications in Early and Metastatic Non-Small Cell Lung Cancer (NSCLC)

Lipid Metabolic Gene Expression is Associated with Decreased Overall Survival and Immunogenicity in KRAS-STK11 NSCLC

Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: a comprehensive multi-center study